C
Chris Smith
Guest
- Johnson & Johnson announced that its coronavirus vaccine candidate is highly effective against COVID-19 complications and death. However, the efficacy rate varies depending on the country, and it’s lower than the Pfizer/BioNTech and Moderna drugs.
- The company said the vaccine was able to protect against severe coronavirus illness that can lead to hospitalization and death. The one-dose drug has been well-tolerated in Phase 3 trials, and no allergic reactions were observed.
- The drug also showed proven effectiveness against the South African B.1.351 mutation, a new coronavirus strain that can evade some drugs and reduce existing vaccines' effectiveness.
- The J&J drug will be submitted to the FDA for Emergency Use Authorization next week, with the US having already preordered 100 million doses.
More than 86.14 million people received at least one COVID-19 vaccine dose as of January 28th, including 26.19 million Americans. But only 8.29 million people are fully vaccinated at this time, including 4.26 million people in the US. That’s because the number of available vaccines that are effective against the novel coronavirus is limited, and production issues as well as vaccination policies still hinder immunization campaigns. Things will hopefully soon improve, as another highly anticipated COVID-19 vaccine candidate has cleared Phase 3 trials successfully, with an Emergency Use Authorization (EUA) review to follow next week.
That’s the Johnson & Johnson vaccine candidate that has a few key advantages over the Pfizer/BioNTech and Moderna drugs. That said, the vaccine isn’t as highly effective as the two mRNA drugs that are already in use.
Today's Top Deal
Everyone's swarming Amazon for these best-selling Powecom KN95 masks
Price: $26.99
Buy Now
Continue reading...
Today's Top Deals
- This special promo basically makes Amazon’s hottest smart home gadget free
- Today’s best deals: Honeywell cloth masks, Prime-only deals, $17 headphones, $60 off Apple Watch S6, more
- Amazon is now letting anyone buy these NIOSH N95 masks for $1.16 each
Trending Right Now:
- Forget $1,400 stimulus checks – this is the best stimulus plan we’ve heard
- Researchers might finally know why some people suffer from Long COVID
- Earth’s latest visitor is about to leave us forever
We finally know how J&J’s one-shot coronavirus vaccine efficacy compares to two-dose vaccines originally appeared on BGR.com on Fri, 29 Jan 2021 at 10:53:59 EDT. Please see our terms for use of feeds.
Via BRG - Boy Genius Report